Diana Lin

Dr. Diana Lin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2019 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
SJSara Javidiparsijani
Sara Javidiparsijani
ABArlen Brickman
Arlen Brickman
DLDiana Lin
Diana Lin
PRPrih Rohra
Prih Rohra
RGRitu Ghai
Ritu Ghai
PGPaolo Gattuso
Paolo Gattuso
Background: Head and neck paraganglioma is a rare neoplasm of the paraganglia. It accounts for <1% of all head and neck tumors. It usually has benign clinical course; however, malignant paraganglioma can only be diagnosed by showing metastatic disease. We undertook a retrospective study to assess the clinical significance of regional lymph nodes metastases in head and neck paragangliomas. Design: From 1993 to 2016, primary head and neck paragangliomas are identified. The patient clinical and histopathologic materials were reviewed. Results: Sixty-five specimens from 62 patients (3 patients with more than 1 specimens) with head and neck paragangliomas were recorded (49 female and 13 males) with mean age of 54 (24-78 years). The locations of the tumors were as follows: carotid body: 30, glomus tympanicum: 11, glomus jugulare: 14, parapharyngeal space: 3, and 1 case each of larynx, skull base, paraglottic area, infratemporal fossa, mastoid, cerebellopontine (CP) angle, and pyriform sinus. On histopathology, we found 5 cases of sclerosing variant. Thirty-two (52%) of the 62 patients had regional lymph node biopsy. Four (12%) of the 32 show metastatic paraganglioma (3 females and 1 male with mean age = 35). Two of the 5 cases of sclerosing variant had positive lymph nodes. No evidence of local recurrence or distant metastasis in the patients with positive lymph nodes with a 6 to 11 years follow-up. One of the 28 patients with negative lymph nodes developed metastatic disease to lumbar spine in 5 years. Conclusion: Metastatic paraganglioma to regional lymph nodes may have indolent clinical behavior, with disease-free survival of up to 11 years. The incidence of metastatic disease in lymph nodes was 4 (12%) of 32. Forty percent (2/5) of the cases with sclerosing variant of paraganglioma had lymph node metastases indicating that this tumor may have a more aggressive histological behavior.

16 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LSLogan Stone
Logan Stone
BKBenjamin Kasten
Benjamin Kasten
SRShilpa Rao
Shilpa Rao
MGManuel. L. Gonzalez
Manuel. L. Gonzalez
TSTodd M. Stevens
Todd M. Stevens
JWJason Warram
Jason Warram
Purpose: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has continually increased during the past several decades. Using transoral robotic surgery (TORS) significantly improves functional outcomes relative to open surgery for OPSCC. However, TORS limits tactile feedback, which is often the most important element of cancer surgery. Fluorescence-guided surgery (FGS) strategies to aid surgeon assessment of malignancy for resection are in various phases of clinical research but exhibit the greatest potential impact for improving patient care when the surgeon receives limited tactile feedback, such as during TORS. Here, we assessed the feasibility of intraoperative fluorescence imaging using panitumumab-IRDye800CW (PAN800) during TORS in patients with OPSCC. Patients and Methods: Twelve consecutive patients with OPSCC were enrolled as part of a nonrandomized, prospective, phase II FGS clinical trial using PAN800. TORS was performed with an integrated robot camera for surgeon assessment of fluorescence. Intraoperative and ex vivo fluorescence signals in tumors and normal tissue were quantified and correlated with histopathology. Results: Intraoperative robot fluorescence views delineated OPSCC from normal tissue throughout the TORS procedure (10.7 mean tumor-to-background ratio), including in tumors with low expression of the molecular target. Tumor-specific fluorescence was consistent with surgeon-defined tumor borders requiring resection. Intraoperative robot fluorescence imaging revealed an OPSCC fragment initially overlooked during TORS based on brightfield views, further substantiating the clinical benefit of this FGS approach. Conclusions: The results from this patient with OPSCC cohort support further clinical assessment of FGS during TORS to aid resection of solid tumors.

1 October 2020 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
CLChen Lin
Chen Lin
YAYurany A. Arevalo
Yurany A. Arevalo
HNHely D. Nanavati
Hely D. Nanavati
DLDiana Lin
Diana Lin
To describe the difference in clinical presentation, including race, of ischemic stroke between patients with and without novel coronavirus disease 2019 (COVID-19), and the association of inflammatory response with stroke severity. This is a retrospective, observational, cross-sectional study of patients (n ​= ​60) admitted with ischemic stroke between late March and early May 2020. All patients were tested for COVID-19 during admission. Demographic, clinical, and laboratory data was collected through electronic medical record review. Descriptive statistics was performed to observe the differences between stroke patients with and without COVID-19 60 hospitalized patients with acute ischemic stroke were included in the analysis. Nine were positive for COVID-19. African-Americans comprised of 55.6% of those that had COVID-19 and stroke and 37.7% of those with only stroke. Stroke patients with COVID-19 had a significantly higher NIHSS [18.4 (8.8)] and neutrophil-to-lymphocyte ratio (NLR) [7.3 (4.2) vs 3.8 (2.8); P ​= ​0.0137] than those without. Those with COVID-19 also had a significantly higher mortality rate (44.4% vs. 7.6%; p ​< ​0.001). We observed a cohort of patients, including a large proportion of African-Americans, who developed ischemic stroke with or without COVID-19. An exaggerated inflammatory response, as indicated by NLR, likely plays a role in stroke severity among COVID-19 patients that concurrently develop ischemic stroke.

31 October 2023 in Surgery
Verified
Journal Article
Closed access
GGGrayson R. Gimblet
Grayson R. Gimblet
JWJason Whitt
Jason Whitt
HHHailey A. Houson
Hailey A. Houson
DLDiana Lin
Diana Lin
RGRachael Guenter
Rachael Guenter
RJRenata Jaskula-Sztul
Renata Jaskula-Sztul

17 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Piyasuda PukkanasutPiyasuda Pukkanasut
Piyasuda Pukkanasut
JWJason Whitt
Jason Whitt
RGRachael Guenter
Rachael Guenter
SLShannon Elizabeth Lynch
Shannon Elizabeth Lynch
CTCarlos A Gallegos Tovar
Carlos A Gallegos Tovar
Sadanandan VeluSadanandan Velu
Sadanandan Velu
Our results from quantitative RT-PCR, Western blotting, immunohistochemistry, and the tissue microarray of medullary thyroid cancer (MTC) cell lines and patient specimens confirm that VGSC subtype NaV1.7 is uniquely expressed in aggressive MTC and not expressed in normal thyroid cells and tissues. We establish the druggability of NaV1.7 in MTC by identifying a novel inhibitor (SV188) and investigate its mode of binding and ability to inhibit INa current in NaV1.7. The whole-cell patch-clamp studies of the SV188 in the NaV1.7 channels expressed in HEK-293 cells show that SV188 inhibited the INa current in NaV1.7 with an IC50 value of 3.6 µM by a voltage- and use-dependent blockade mechanism, and the maximum inhibitory effect is observed when the channel is open. SV188 inhibited the viability of MTC cell lines, MZ-CRC-1 and TT, with IC50 values of 8.47 μM and 9.32 μM, respectively, and significantly inhibited the invasion of MZ-CRC-1 cells by 35% and 52% at 3 μM and 6 μM, respectively. In contrast, SV188 had no effect on the invasion of TT cells derived from primary tumor, which have lower basal expression of NaV1.7. In addition, SV188 at 3 μM significantly inhibited the migration of MZ-CRC-1 and TT cells by 27% and 57%, respectively.

15 September 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
AGAndrea Gillis
Andrea Gillis
RZRui Zheng-Pywell
Rui Zheng-Pywell
CMChandler McLeod
Chandler McLeod
DWDezhi Wang
Dezhi Wang
JNJohn M. Ness
John M. Ness
DLDiana Lin
Diana Lin